Alerta

PHARMACEUTICAL COMPOSITION CONTAINING CBFbeta-EXPRESSING VASCULAR SMOOTH MUSCLE CELLS OR CULTURE FLUID THEREOF AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AGE-RELATED DISEASES

Resumen de: US20260097084A1

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

METHODS AND SYSTEMS FOR RAPID DETECTION OF STROKE AND DETERMINATION OF ONSET VIA NEUROINFLAMMATION BIOMARKERS

Resumen de: US20260098869A1

Disclosed herein are methods, devices, and systems useful for identifying a subject having suffered a stroke and for identifying onset time of the stroke. In many embodiments, accurately determining a stroke and its onset allows for use of therapeutic drugs to alleviate symptoms that may not be available without these determinations. In many embodiments, the methods, devices, and systems are useful in identifying and analyzing IL-6 levels in the subject's blood. In some embodiments, the biomarker is detected using ELISA, SPR, molecular array, SiMoA, Ella, ECL.

Application of 4-VPS in preparation of kit for screening and/or diagnosing hypertensive kidney injury

Resumen de: CN121805570A

The invention relates to the technical field of biological medicine, in particular to application of 4-VPS in preparation of a kit for screening and/or diagnosing hypertensive kidney injury. According to the invention, a detection sample of 4-VPS is peripheral blood, and the sample is convenient to collect, minimally invasive and easy to popularize clinically; meanwhile, functional experiments prove that 4-VPS can directly induce kidney injury, early diagnosis of hypertensive nephropathy is achieved through 4-VPS, a patient can receive intervention treatment in the early stage of the disease, the disease is delayed or even prevented from developing into the end-stage nephropathy, the requirement of the patient for subsequent dialysis treatment or kidney transplantation is reduced, personal medical expenditure is reduced, and the treatment cost is reduced. Meanwhile, consumption of social medical resources is reduced, and remarkable economic benefits are achieved.

Application of STAT1 inhibitor and detection preparation and construction method of vascular transplantation reconstruction model

Resumen de: CN121796597A

The invention discloses application of an STAT1 inhibitor and a detection preparation and a construction method of a vascular transplantation remodeling model, and belongs to the technical field of transplantation vascular remodeling treatment and diagnosis. The STAT1 is used as a target spot for preventing, treating and/or relieving the transplanted vascular remodeling and related diseases, meanwhile, the STAT1 is used as a biomarker for diagnosing the transplanted vascular remodeling, and a new thought is provided for preventing, treating and/or relieving the transplanted vascular remodeling and the related diseases.

Pharmaceutical application of RNA helicase DHX8

Resumen de: CN121802037A

The invention discloses pharmaceutical application of RNA helicase DHX8, including application of the RNA helicase DHX8 in aortic dissection diagnosis, treatment and drug development. It is found for the first time that DHX8 is significantly down-regulated in aortic dissection patients, animal models and vascular endothelial cells, and overexpression of DHX8 can effectively up-regulate endothelial cell tight connection related genes and repair the endothelial barrier function. The Si DHX8 is used for transfecting human umbilical vein endothelial cells (HUVECs), and the DHX8 is knocked down, so that the tight connection gene OCLN is obviously reduced; when the OE DHX8 plasmid is used for transfecting the HUVECs and overexpressing the DHX8, the tight connection genes OCLN, JAM-A, ZO-1 and VE-cadherin are found to be obviously up-regulated. The DHX8 is used as a new target for aortic dissection diagnosis and treatment, and a detection reagent, a gene therapy vector and an agonist drug of the DHX8 have important clinical transformation values.

CFTSR gene, CFTSR gene simulant and application of CFTSR gene simulant

Nº publicación: CN121801908A 07/04/2026

Solicitante:

SHANDONG MATERNAL AND CHILD HEALTH HOSPITAL
\u5C71\u4E1C\u7701\u5987\u5E7C\u4FDD\u5065\u9662

Resumen de: CN121801908A

The invention belongs to the technical field of biology, and particularly relates to a CFTSR gene, a CFTSR gene simulant and application of the CFTSR gene simulant. The nucleic acid sequence of the CFTSR gene is as shown in SEO ID NO. 1. The nucleic acid sequence of the CFTSR gene simulant is as shown in SEO ID NO. 2. The CFTSR gene provided by the invention can be used as a marker for fibroblast activation, and is used for a kit for detecting cardiac fibroblast activation. The CFTSR gene simulant can be used as a therapeutic drug for myocardial infarction injury, and the overexpression of the CFTSR gene can significantly inhibit the proliferation of fibroblasts and activate the repair of damaged myocardial tissues. Based on CFTSR mimics, a simulant of the CFTSR gene is constructed, and the simulant can be conveyed to the position of a heart lesion and can be used as a medicine for treating myocardial infarction injury, so that effective treatment of the lesion is realized.